国产注射用重组人尿激酶原治疗急性心肌梗死疗效观察  

Therapeutic effect of recombinant prourokinase on the patients with acute myocardial infarction

作　　者：刘闯[1] 张金盈[1] 黄振文[1] 李华[2] 邱春光[1] 党瑜华[1] 赵洛莎[1] 张彦周[1] 张晓[1] 张慧琴[3] 刘保山[4] 

机构地区：[1]郑州大学第一附属医院心内科,郑州450052 [2]郑州大学第一附属医院老年病科,郑州450052 [3]郑州大学第一附属医院医务部,郑州450052 [4]郑州大学第一附属医院放射科,郑州450052

出　　处：《郑州大学学报（医学版）》2004年第6期1051-1054,共4页Journal of Zhengzhou University(Medical Sciences)

摘　　要：目的 :观察国产注射用重组人尿激酶原 (rhPro-UK)治疗急性心肌梗死 (AMI)的效果和副作用。方法 :将31例发病 6h内的AMI患者随机分为rhPro -UK组 (n =16 )和尿激酶 (UK)组 (n =15 )。rhPro -UK组取rhPro -UK2 0mg溶于 10ml生理盐水中 3min内静脉注射 ,另取 2 0mg溶于 90ml生理盐水中 30min内静脉滴注完毕。尿激酶组取UK 15 0万单位溶于 10 0ml生理盐水中 30min内静脉滴注完毕。在溶栓 90min时进行选择性冠状动脉造影 ,评价梗死相关动脉开通情况。评价出血并发症以及生化指标变化情况。结果 :rhPro -UK组总的梗死相关动脉开通率为 74 .9% ,UK组为 6 6 .7% (P =0 .0 4 1)。rhPro -UK组无颅内出血 ,UK组有 1例致命性颅内出血 ;其余出血并发症以及生化指标变化情况 2组差异无统计学意义。结论 :AMI时应用国产rhPro -UK进行静脉溶栓成功率高 ,使用安全 。Aim: To investigate the therapeutic effect and side effect of recombinant prourokinase (rhPro-UK) on the patients with acute myocardial infarction. Methods: A total of 31 cases of acute myocardial infarction treated by thrombolytic agents within 6 hours after onset were divided randomly into rhPro-UK group(n=16) and urokinase (UK) group(n=15). In rhPro-UK group, 20 mg rhPro-UK was used by intravenous injection within 3 minutes, then 20mg rhPro-UK was injected into vein within 30 minutes. In UK group, 1.5 million units UK was used by intravenous injection within 30 minutes. The dilation of infarct-related coronary artery was evaluated by coronary angiography. Results: The dilation rates were 74.9% in rhPro-UK group and 66.7% in UK group,respectively(P=0.041). There was no intracranial hemorrhage in rhPro-UK group. However in UK group, one patient experienced intracranial hemorrhage. Conclusion: rhPro-UK is safe and effective for the patients with acute myocardial infarction.

关 键 词：急性心肌梗死 重组人尿激酶原 尿激酶 溶栓 

分 类 号：R542.2[医药卫生—心血管疾病]